Sharat Singh
Chief Tech/Sci/R&D Officer at PROSPECT RESOURCES LIMITED
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Eric d'Esparbes | M | 56 | 5 years | |
| Jeffrey Alter | M | 61 | 5 years | |
| Clarke Neumann | M | 60 | 10 years | |
| Mark Wheatley | M | 62 | 3 years | |
| Ian John Goldberg | M | - | 3 years | |
| Jill Howe | F | 48 | 3 years | |
| Adi Mohanty | M | 57 | 3 years | |
| Lynne Powell | F | 57 | 5 years | |
| Jeffrey Allen Ferrell | M | 49 | 10 years | |
| Brian Kotzin | M | 74 | 5 years | |
| Samuel Hosack | M | - | 6 years | |
| Robyn Hatton | F | - | 11 years | |
| Ariella Kelman | M | - | 1 years | |
| John Maketo | M | - | 5 years | |
| Michael Rhode | M | - | - | |
| Allison Luo | M | 50 | 7 years | |
| Roger Tyler | M | - | 11 years | |
| Guarav Gupta | M | - | 1 years | |
| Harry Miller | M | - | 1 years | |
| David Broomfield | M | - | 2 years | |
| Zivanayi L. Rusike | M | 65 | 11 years | |
| Gerry Fahey | M | 71 | 11 years | |
| Paul W. Shabram | M | - | 2 years | |
| James Winch | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Herb H. Hooper | M | 60 |
ACLARA Biosciences, Inc.
 ACLARA Biosciences, Inc. Medical SpecialtiesHealth Technology ACLARA Biosciences, Inc. discovers, develops and markets innovative products to guide and improve treatment of serious viral, immunologic, and oncologic diseases. | - |
| Alfred G. Merriweather | M | 70 |
ACLARA Biosciences, Inc.
ACLARA Biosciences, Inc. Medical SpecialtiesHealth Technology ACLARA Biosciences, Inc. discovers, develops and markets innovative products to guide and improve treatment of serious viral, immunologic, and oncologic diseases. | 3 years |
| Tom Baruch | M | 85 |
ACLARA Biosciences, Inc.
ACLARA Biosciences, Inc. Medical SpecialtiesHealth Technology ACLARA Biosciences, Inc. discovers, develops and markets innovative products to guide and improve treatment of serious viral, immunologic, and oncologic diseases. | - |
| Thomas G. Klopack | M | - |
ACLARA Biosciences, Inc.
ACLARA Biosciences, Inc. Medical SpecialtiesHealth Technology ACLARA Biosciences, Inc. discovers, develops and markets innovative products to guide and improve treatment of serious viral, immunologic, and oncologic diseases. | - |
| John Mendlein | M | 64 |
ACLARA Biosciences, Inc.
ACLARA Biosciences, Inc. Medical SpecialtiesHealth Technology ACLARA Biosciences, Inc. discovers, develops and markets innovative products to guide and improve treatment of serious viral, immunologic, and oncologic diseases. | 1 years |
| André F. Marion | M | 88 |
ACLARA Biosciences, Inc.
ACLARA Biosciences, Inc. Medical SpecialtiesHealth Technology ACLARA Biosciences, Inc. discovers, develops and markets innovative products to guide and improve treatment of serious viral, immunologic, and oncologic diseases. | - |
| Stephen C. Macevicz | M | - |
ACLARA Biosciences, Inc.
ACLARA Biosciences, Inc. Medical SpecialtiesHealth Technology ACLARA Biosciences, Inc. discovers, develops and markets innovative products to guide and improve treatment of serious viral, immunologic, and oncologic diseases. | - |
| Kevin Tang | M | 57 |
ACLARA Biosciences, Inc.
ACLARA Biosciences, Inc. Medical SpecialtiesHealth Technology ACLARA Biosciences, Inc. discovers, develops and markets innovative products to guide and improve treatment of serious viral, immunologic, and oncologic diseases. | - |
| Michael Dunn | M | 68 |
ACLARA Biosciences, Inc.
ACLARA Biosciences, Inc. Medical SpecialtiesHealth Technology ACLARA Biosciences, Inc. discovers, develops and markets innovative products to guide and improve treatment of serious viral, immunologic, and oncologic diseases. | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 22 | 66.67% |
| Australia | 11 | 33.33% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Sharat Singh
- Personal Network
